Gene Transfer Technologies Global Market Report 2025

The gene transfer technologies market size has grown rapidly in recent years. It will grow from $3.97 billion in 2024 to $4.54 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be linked to increasing demand for genetic modification research, a growing focus on personalized medicine, rising government funding for biotechnology research, expansion of gene therapy clinical trials, and increasing academic and industry collaborations.

The gene transfer technologies market size is expected to see rapid growth in the next few years. It will grow to $7.7 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be driven by growing adoption of advanced gene delivery systems, rising investment in genetic engineering and synthetic biology, increasing applications in rare disease treatment, expansion of biopharmaceutical R&D activities, and growing regulatory support for gene-based therapies. Major trends in the forecast period include technological advancements in gene editing tools, continuous innovations in viral and non-viral vectors, increasing research and development in gene delivery platforms, the development of next-generation gene transfer systems, and advancements in precision genetic engineering techniques.

The rising prevalence of genetic disorders is expected to drive the growth of the gene transfer technologies market. Genetic disorders are caused by changes in one or more genes or chromosomes that impair normal biological functions. Their increasing prevalence is largely due to improved diagnosis and reporting, aging populations, and higher survival rates of affected infants resulting from better clinical care. Gene transfer technologies enable the targeted delivery and correction of faulty genes, supporting the development of gene therapies, precision treatments, and advanced research capabilities. For instance, in February 2025, the World Health Organization reported that over 300 million people globally live with rare diseases, approximately 70% of which originate in childhood. This rising prevalence is thus fueling demand for gene transfer technologies.

Companies in the gene transfer technologies market are investing in advanced manufacturing platforms and integrated contract development and manufacturing organization (CDMO) services to accelerate cell and gene therapy development, improve scalability, and ensure regulatory compliance. Integrated CDMO services combine product development, process optimization, and large-scale manufacturing within a single provider, streamlining production and reducing time-to-market. For example, in October 2025, AGC Biologics, a US-based biopharmaceutical CDMO, launched a dedicated Cell and Gene Therapy Business Division to strengthen its end-to-end development and manufacturing capabilities for plasmid DNA, viral vectors, and cell therapies. This initiative aims to enhance process efficiency, streamline clinical-to-commercial scale transition, and support innovation in gene transfer therapies worldwide.

In July 2024, Genezen, a US-based CDMO, acquired uniQure’s commercial gene therapy operations for an undisclosed amount. Through this acquisition, Genezen aims to expand its commercial gene therapy capabilities and accelerate market access for advanced therapies. UniQure is a Netherlands-based biopharmaceutical company focused on developing and commercializing gene therapies for serious genetic diseases.

Major companies operating in the gene transfer technologies market are Thermo Fisher Scientific, Merck KGaA, Evonik Industries, Lonza Group AG, Agilent Technologies Inc., Charles River Laboratories, Sartorius AG, Bio-Techne Corporation, Takara Bio Inc., Aldevron, Regenxbio Inc., CureVac AG, OriGene Technologies, Precision NanoSystems, 4D Molecular Therapeutics, Synthego Corporation, Addgene, Acuitas Therapeutics, Transposagen Biopharmaceuticals, Vigene Biosciences.

North America was the largest region in the gene transfer technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene transfer technologies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gene transfer technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The gene transfer technologies market research report is one of a series of new reports that provides gene transfer technologies market statistics, including the gene transfer technologies industry global market size, regional shares, competitors with the gene transfer technologies market share, detailed gene transfer technologies market segments, market trends, and opportunities, and any further data you may need to thrive in the gene transfer technologies industry. This gene transfer technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Gene transfer technologies refer to advanced techniques used to introduce foreign genetic material into cells to modify or regulate their genetic composition. These technologies are essential in developing gene therapies, conducting genetic research, and producing recombinant proteins. By enabling precise genetic alterations, they support the treatment of inherited disorders and the progress of personalized medicine.

The key products in gene transfer technologies include reagents, kits, and assays, consumables, instruments, and others. Reagents, kits, and assays refer to essential tools used to facilitate and monitor the gene transfer process by enabling the effective delivery and expression of genetic material in target cells. Various modes include viral methods such as retrovirus, adenovirus, and adeno-associated virus, as well as non-viral approaches like electroporation and gene gun techniques. The key methods include in vivo, ex vivo, and in vitro. Major applications include gene therapy, personalized medicine, regenerative medicine, and vaccine development, with primary end users such as academic and research institutes, biopharmaceutical companies, and contract research organizations.

The gene transfer technologies market consists of revenues earned by entities by providing services such as cell line development services, regulatory and compliance support services, and custom assay development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene transfer technologies market also includes sales of electroporation devices, microinjection systems, cell culture media, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.